Hong Kong's SSY Group H1 profit rises on infusion solutions growth

SSY

26/08/2026 05:16

Overview
Hong Kong pharmaceutical maker's H1 revenue rose 9.9% yr/yr to HK$2,361 mln
Net profit attributable to shareholders rose 13% to HK$320 mln for the period
Company raised interim dividend by 10%

Outlook
SSY Group plans to strengthen operations and stabilize expectations in H2 2026
Company aims to accelerate overseas market expansion and maintain steady bidding success in procurement
SSY Group expects to submit applications for 16 new product specifications and obtain approvals for 58 in H2 2026

Result Drivers
INFUSION SOLUTIONS GROWTH - Sales volume and revenue of infusion solutions rose sharply, with sales volume up 21.4% and revenue up 24% yr/yr, driven by expanded market coverage and increased demand
CENTRALISED PROCUREMENT - Participation in national and local centralised procurement projects helped drive rapid volume growth and expand market share for new and existing products
EXPORT SALES EXPANSION - Export sales of preparations, infusion solutions and ampoule injections increased, with export sales of infusion solutions up 24% and ampoule injections up 32% yr/yr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
HK$2,361 mln
 
H1 Net Income Attributable
 
HK$320 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for SSY Group Ltd is HK$3.08, about 22.5% above its August 25 closing price of HK$2.52
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Reuters Recommended Reads
Aug 25 - China's Shandong Xinhua profit drops on domestic, international competition
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-26/ac295c82-f7cf-44e7-b20f-d4e5a5766842.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)